This tool provides important facts about the processes involved in developing recombinant factor VIII therapies.
This tool covers the five steps of factor VIII development:
Contact your Baxter sales representative today to order your copy of the flipchart.
ADVATE [Antihemophilic Factor (Recombinant), Plasma/Albumin-Free Method] is indicated in hemophilia A (classical hemophilia) for the prevention and control of bleeding episodes and for perioperative management of patients with hemophilia A.
ADVATE is not indicated for the treatment of von Willebrand's disease.
Important Safety Information
ADVATE should be administered cautiously in patients with previous hypersensitivity to constituents of Factor VIII preparations or known sensitivity to mouse or hamster proteins.
The formation of inhibitors has been observed with all Factor VIII products, including ADVATE.
The most common related adverse reactions observed during clinical studies include: strange taste in mouth, headache, dizziness, and flushing.
ADVATE supplied with BAXJECT II Full Prescribing Information (PDF).
